MLKL and cancer: Some studies believe that RIPK1 has no kinase activity in complex I. inhibiting RIPK1 activity by necrostatin-1 has no effect on TNF-induced NF-κB signaling pathway, but it can prevent the formation of complex IIB from inhibiting necroptosis.291,292 Therefore, the role of RIPK1 in cells can determine whether cancer cells survive or undergo necroptosis through targeted drugs.292 RIPK3 activation of MLKL is a key regulatory pathway in necroptosis.